Looking Better: Digital therapy reduces liver fat in 90 days : vimarsana.com

Better Therapeutics Inc.’s prescription digital therapeutic (PDT) received U.S. FDA breakthrough device designation for metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease that increases the risk of cirrhosis, liver failure and liver cancer but has few good treatments available.

Related Keywords

, Better Therapeutics Inc , Better Therapeutics , Bioworld Medtech , Hepatology , Prescription Digital Therapeutic , Dpdt , Metabolic Dysfunction Associated Liver Disease , Metabolic Dysfunction Associated Steatotic Liver Disease , Masld , Non Alcoholic Fatty Liver Disease , Nafld , Non Alcoholic Steatohepatitis , Nash , Metabolic Dysfunction Associated Steatohepatitis , Mash , Fibrosis , Breakthrough Device Designation , Us , Fda , Regulatory ,